替米考星(Tilmicosin)对鸡败血霉形体感染的药效学

以试管二倍稀释法测定替米考星 (Tilmicosin)及对照药物强力霉素、红霉素、泰乐菌素对鸡败血霉形体的最小抑菌浓度分别为 0 .0 0 6 2 5、0 .0 2 5、0 .0 2 5、0 .1m g/ L ,进行了替米考星对鸡败血霉形体的体内药效学研究。结果 ,替米考星以 5 0、75、10 0 mg/ L 饮水给药 5 d,对实验性感染鸡败血霉形体有显著疗效 ,用药组增重均显著高于对照组 (P<0 .0 5或 P<0 .0 1) ,并能明显减少抗体阳性反应率 ,极显著地减少气囊损伤记分 (P<0 .0 1)     

A comparison of the efficacy of danofloxacin and tylosin in the control of Mycoplasma gallisepticum infection in broiler chicks

Groups of chicks were infected with a virulent strain of Mycoplasma gallisepticum (MG) and treated with either danofloxacin or tylosin while one infected group was left untreated and a further group was uninfected and untreated. Control of
clinical signs and mortality was better with danofloxacin than tylosin and there
was significantly (P <0.05)greater weight gain with danofloxacin at 21 days
after infection. However ht necropsy the prevalence of lesions of the airsac walls
was similar in both groups. MG was recovered from fewer live chicks for the first
week following treatment with danofloxacin, but at 2 weeks and at necropsy, at
the termination of the experiment, it was recovered from a similar proportion of
birds in both treated groups. This was reflected also in the serological results at
the end of the trial.     

Effect of giving enrofloxacin in the diet to pigs experimentally infected with Actinobacillus pleuropneumoniae

Three groups of 16 pigs were exposed individually when four weeks old to intranasal infection with 10(8.9) viable Actinobacillus pleuropneumoniae (serovar 3, strain 2/(10P2); a fourth group was kept in isolation from the others as uninfected controls. Seven days later the 62 surviving animals were killed and necropsied. The organism had caused typical, mainly subacute disease in 12 of the 16 unmedicated animals but in only two of the 16 which had had continuous access to a diet containing 150ppm of enrofloxacin from four hours before exposure to infection, and in six of the 16 given 32 ppm enrofloxacin. However, only 150 ppm enrofloxacin produced marked control of the infection in terms of reduced average severity of thoracic lesions and much reduced prevalence of the organism in the lung at necropsy, and the mean weight gain (1.55 kg) and feed conversion efficiency (2.08) of this infected group over seven days were similar to those of the unmedicated, uninfected controls (1.67 kg and 2.25). The infected but untreated group on average produced detectable antibody seven days after infection whereas in the infected and medicated groups a specific response against serovar 3 was absent.     

柔嫩艾美球虫常州株对5种抗球虫药的抗药性分析

将柔嫩艾美耳球虫(E.tenella)常州分离株感染14日龄苏禽黄羽肉鸡,设立5个用药组、1个感染不用药对照组和1个不感染不用药对照组,以相对卵囊产量、病变记分减少率、最适抗球虫百分数和抗球虫指数为指标对该虫株对球虫宁、地克珠利、马杜霉素、磺胺氯吡嗪、癸氧喹酯5种常用抗球虫药的抗药性进行了综合评定,分析了该地区球虫的抗药性及用药对策。结果表明,该虫株对癸氧喹酯敏感,对球虫宁、地克珠利、马杜霉素、磺胺氯吡嗪具有完全抗药性,提示目前常州地区球虫抗药性非常严重,癸氧喹酯抗球虫疗效最好,其他药物应合理使用、应慎用、减少或暂停使用。     

柔嫩艾美耳球虫扬州分离株对8种抗球虫药的抗药性

将柔嫩艾美耳球虫(Eimeria tenella)扬州分离株感染14日龄苏禽黄羽肉鸡,设立8个用药组、1个感染不用药对照组和1个不感染不用药对照组,以相对卵囊产量、病变记分减少率、最适抗球虫百分数和抗球虫指数为指标对该虫株对盐霉素、马杜拉霉素、球痢灵、氯羟吡啶、氨丙啉、尼卡巴嗪、甲基三嗪酮、地克珠利等8种常用抗球虫药的抗药性进行了综合评定,分析了该地区球虫的抗药性及对策。结果表明,该虫株对甲基三嗪酮敏感,对氨丙啉具有中度抗药性,对盐霉素、马杜拉霉素、球痢灵、氯羟吡啶、尼卡巴嗪、地克珠利等其他6种药物具有完全抗药性。提示目前在扬州地区甲基三嗪酮抗球虫疗效最好,氨丙琳效果稍差,应合理使用,盐霉素等其他6种药物应慎用、减少或暂停使用。     

Efficacy of tilmicosin in the control of experimentally induced Actinobacillus pleuropneumoniae infection in swine

The efficacy of tilmicosin administered in the feed to control Actinobacillus pleuropneumoniae infections in pigs was evaluated through a multisite, multitrial study. For each of 6 trials, 48 pigs (stratified by weight and sex) were randomly assigned to 6 to 8 pens. Medicated feed containing tilmicosin (200 g/t) and unmedicated feed were randomly assigned at the pen level and were provided ad libitum from day −7 to trial termination (day 14). Seeder pigs (inoculated intranasally with A. pleuropneumoniae serotype 1 and showing signs of clinical disease) were introduced to each pen on day 0. Rates of death, gross lesions, and culture of A. pleuropneumoniae at necropsy, clinical scores, average daily gain in weight, and average body temperature were compared between the medicated and unmedicated pigs. Compared with the unmedicated pigs, significantly fewer (P < 0.05) pigs given tilmicosin had lesions typical of A. pleuropneumoniae or had A. pleuropneumoniae isolated from their tissues at necropsy. Together with a significant reduction (P < 0.05) in the average percentage of pneumonic lung involvement (both visually and by weight), there were reductions in the numbers of pigs with moderate and severe pneumonic lung lesions and with A. pleuropneumoniae associated mortality. With tilmicosin treatment, the average daily weight gain, daily temperature, abdominal appearance, attitude, and respiration were also significantly better (P < 0.05). The results of this study demonstrate the in vivo effectiveness of tilmicosin (200 g/t) in controlling pleuropneumonia among swine experimentally infected with A. pleuropneumoniae.     

氟罗沙星对鸡败血支原体和大肠杆菌混合感染的疗效

以人工诱发鸡败血霉形体和大肠杆菌混合感染模型,评价氟罗沙星的疗效。按每升水加入２５ｍｇ、５０ｍｇ及１００ｍｇ氟罗沙星及５０ｍｇ环丙沙星的用量给病鸡饮水给药,连续５天,对混合感染鸡的治愈率分别是８６．７％、９０．０％、９０．０％及８３．３％,而感染对照组的死亡率为６３．３％;用药组的相对增重率分别为１０１．３％、１０５．７％、１０７．２％及１０２．４％,均显著高于感染对照组（５８５．５％,Ｐ〈０．０１）     

Prophylactic medication of feedlot calves with tilmicosin

The parenteral administration to calves of the antibiotic tilmicosin either on arrival at a feedlot or 72 hours later was evaluated in a group of 308 steer calves. The calves were allotted to 24 pens so that there were eight replicates of the two medicated groups and eight replicates of the control group. The need for veterinary treatment was reduced significantly (P less than 0.05) during the first month of the feeding period in the two medicated groups. The medicated groups had an improved average daily weight gain (P less than 0.01) over the trial period compared with the non-medicated animals. This improved average daily gain by the medicated groups was not reduced when animals with respiratory disease were excluded from the calculations. The medicated groups also had an improved feed conversion efficiency (P less than 0.01) over the first 60 days of the feeding period compared with the non-medicated animals.     

Long-acting antibiotic formulations in the treatment of calf pneumonia: a comparative study of tilmicosin and oxytetracycline

The treatment of an outbreak of acute pneumonia in 50 four- to eight-month-old Friesian and Friesian cross calves is described. At the first visit (day 0) 16 calves received 20 mg/kg bodyweight of oxytetracycline dihydrate intramuscularly and 15 received 10 mg/kg of the macrolide tilmicosin subcutaneously. The remaining 19 in-contact animals were not considered ill enough to be included in the trial and received 20 mg/kg of oxytetracycline dihydrate. The rectal temperature, demeanour, respiratory rate and respiratory effort of each calf was assessed on days 1, 2, 3, 9, 14, 21 and 28, and calves which had not responded were given repeat injections of the same antibiotic. All the calves recovered from the outbreak and of the 19 calves treated strategically, three required a second injection. Among the calves with clinical pneumonia, fewer treatments (P less than 0.01) were required by those treated with tilmicosin. The rectal temperatures of both groups decreased (P less than 0.05) after the first injection, but on day 3 the decrease was greater (P less than 0.05) in the group treated with tilmicosin. Respiratory rates varied widely but respiratory effort was less (P less than 0.05) on day 2 in the calves treated with tilmicosin. When long-acting antibiotic injections are used to treat enzootic pneumonia it is suggested that a second visit should be made on day 3 to assess the animals' response to treatment.     

Effect of mass medication with antibiotics at feedlot entry on the health and growth rate of cattle destined for the Australian domestic market

OBJECTIVE: To examine the effectiveness of mass medication with long acting antibiotics at feedlot entry on lot-fed Australian domestic cattle during a period of high risk for bovine respiratory disease (BRD). DESIGN: Systematic allocation at feedlot entry of tilmicosin, long acting oxytetracycline or no antibiotic treatment, to cattle lot fed for the Australian domestic market. Comparisons of growth rate, disease occurrence and mortality were made between the groups at the conclusion of the feeding period. RESULTS: Cattle medicated with tilmicosin at 10 mg/kg body weight on entry to the feedlot grew 0.08 kg/d faster than cattle medicated with oxytetracycline at 20 mg/kg body weight and non-medicated cattle. There was no significant difference in growth rate between oxytetracycline medicated cattle and cattle not medicated with antibiotic at feedlot entry. Cattle medicated with tilmicosin at feedlot entry had 8 fewer cases of disease per 100 animals compared with cattle not medicated with antibiotic at feedlot entry. There was no significant difference in disease occurrence between oxytetracycline medicated cattle and those not medicated with antibiotic at feedlot entry. CONCLUSION: Mass medication with tilmicosin at feedlot entry of cattle destined for the Australian domestic market may be used to reduce disease occurrence and increase growth rate during periods of high risk for BRD.     

Effects of oral administration of tilmicosin on pulmonary inflammation in piglets experimentally infected with Actinobacillus pleuropneumoniae

OBJECTIVES: To determine the effects of oral administration of tilmicosin in piglets experimentally infected with Actinobacillus pleuropneumoniae. ANIMALS: Forty 3-week-old specific-pathogen free piglets. PROCEDURES: Piglets were assigned to 1 of 4 groups as follows: 1) uninfected sham-treated control piglets; 2) infected untreated piglets that were intratracheally inoculated with 10(7) CFUs of A pleuropneumoniae; 3) infected treated piglets that were intratracheally inoculated with A pleuropneumoniae and received tilmicosin in feed (400 ppm [microg/g]) for 7 days prior to inoculation; or 4) infected treated piglets that were intratracheally inoculated with A pleuropneumoniae and received chlortetracycline (CTC) in feed (1100 ppm [microg/gl) for 7 days prior to inoculation. Bronchoalveolar lavage (BAL) fluid and lung tissue specimens of piglets for each group were evaluated at 3 or 24 hours after inoculation. For each time point, 4 to 6 piglets/group were studied. RESULTS: Feeding of CTC and tilmicosin decreased bacterial load in lungs of infected piglets. Tilmicosin delivered in feed, but not CTC, enhanced apoptosis in porcine BAL fluid leukocytes. This was associated with a decrease in LTB4 concentrations in BAL fluid of tilmicosin-treated piglets, compared with untreated and CTC-treated piglets, and also with a significant decrease in the number of pulmonary lesions. Tilmicosin inhibited infection-induced increases in rectal temperatures, as measured in untreated and CTC-treated piglets. Pulmonary neutrophil infiltration and prostaglandin E2 concentrations in the BAL fluid were not significantly different among groups at any time. CONCLUSIONS AND CLINICAL RELEVANCE: Oral administration of tilmicosin to infected piglets induces apoptosis in BAL fluid leukocytes and decreases BAL fluid LTB4 concentrations and inflammatory lung lesions.     

柔嫩艾美耳球虫莆田株抗药性研究

为掌握鸡场球虫抗药程度,以便制定合理用药方案,采集福建省莆田市某鸡场盲肠球虫,进行柔嫩艾美耳球虫单卵囊分离和纯化;采用鸡体试验法,设立5个用药组、1个感染不用药对照组和1个不感染不用药对照组,以病变记分减少率(Reduction of lesion sores,RLS)、抗球虫指数(Anticoccidial index,ACI)、相对盲肠卵囊产量(Relative at oocyst production,ROP)和最适抗球虫活性百分率(Percent of optimum anticoccidial activity,POAA)4项为指标,检测该球虫对癸氧喹酯、尼卡巴嗪、地克珠利、二硝托胺和氯苯胍等5种常用抗球虫药的抗药性。结果表明:该虫株对癸氧喹酯敏感,对地克珠利、二硝托胺和氯苯胍具有完全抗药性,对尼卡巴嗪为中度抗药性,说明目前莆田市球虫抗药性非常严重,癸氧喹酯可用于抗球虫病,其他药物应慎用或暂停使用。     

Efficacy of azithromycin dihydrate in treatment of cryptosporidiosis in naturally infected dairy calves

The objective of this study was to evaluate the therapeutic efficacy of azithromycin treatment of cryptosporidiosis in naturally infected calves under field conditions. Fifty Holstein calves with cryptosporidiosis infection were divided into 5 groups: 1 group (10 calves) was unmedicated and served as the control group and was given distilled water only, whereas the other groups (10 animals per group) were medicated orally with azithromycin at the doses of 500 (group 1), 1,000 (group 2), 1,500 (group 3), and 2,000 mg (group 4) PO once daily for 7 days. The animals were examined clinically and fecal samples were collected on the 1st (inclusion day), 7th, 14th, and 21st days of the study. Drug efficacy was assessed by evaluating diarrhea, oocyst shedding, and weight gains from days 1 to 21 (4 assessments). Significant differences were observed in reductions of oocyst shedding (P < .05) and the fecal diarrhea incidence (P < .05) in groups 3 and 4 when compared with groups 1 and 2 and the control group. Weight gain of medicated calves was significantly higher than that of the unmedicated calves throughout the study (P < .05). The drug significantly suppressed oocyst shedding and resulted in significant improvements in clinical signs. Therefore, this suppression may have significant effect on the reduction of environmental contamination by cryptosporidial oocysts. From the economic point view, authors suggest that the most effective dose of azithromycin for the treatment of cryptosporidiosis in calves should be at 1,500 mg/d for 7 days.     

Determination of florfenicol dose rate in feed for control of mortality in Nile tilapia infected with Streptococcus iniae

A dose titration study was conducted to determine the dosage of florfenicol (FFC) in feed to control Streptococcus iniae-associated mortality in Nile tilapia Oreochromis niloticus. Six tanks were assigned to each of five treatments: (1) not challenged with S. iniae and fed unmedicated feed; (2) challenged with S. iniae by injection and fed unmedicated feed; (3) challenged with S. iniae and given FFC at 5 mg/kg of body weight (bw) in medicated feed; (4) challenged with S. iniae and given 10 mg FFC/kg bw; and (5) challenged with S. iniae and given 15 mg FFC/kg bw. Treatment was initiated the day after inoculation, and feed was administered for 10 d. Cumulative mortality was 0% in the unchallenged, untreated group; 35.8 +/- 4.4% (mean +/- SE) in the challenged, unmedicated group; 19.2 +/- 2.7% in the 5-mg/kg treated group, 12.5 +/- 3.8% in the 10-mg/kg group, and 2.5 +/- 1.1% in the 15-mg/kg group. The cumulative mortality was significantly less in each challenged, FFC-treated group than in the challenged, unmedicated controls (5 mg/ kg: P = 0.0156; 10 mg/kg: P = 0.0007; 15 mg/kg: P < 0.0001). The efficacy of the 10- and 15-mg/kg FFC dosages was studied in a separate dose confirmation study. Fish in all tanks were injected with S. iniae. At 4 h postinoculation, 10 tanks were assigned to each of three feed treatments: (1) unmedicated feed; (2) 10 mg FFC/kg bw; and (3) 15 mg FFC/kg bw. Cumulative mortality was 20.5 +/- 2.0% in the challenged, unmedicated group; 11.0 +/- 2.1% in the 10-mg/kg group; and 5.5 +/- 2.4% in the 15-mg/kg group. Mortality was significantly less in the medicated groups than in the challenged, unmedicated control group (10 mg/kg: P = 0.0270; 15 mg/kg: P = 0.0007). Fish in both studies were necropsied, cultured for bacteria, and examined for gross lesions. The minimum inhibitory concentration of FFC against S. iniae in both studies ranged from 0.5 to 1.0 microg/mL. Florfenicol was palatable, safe, and efficacious for control of Nile tilapia mortality due to S. iniae infection.     

氧氟沙星对霉形体与大肠杆菌合并感染鸡的药效学研究

以试管两倍稀释法测得氧氟沙星及其对照药物恩诺沙星、洛美沙星和强力霉素对鸡败血霉形体的最小抑菌浓度分别为０．００６２５、０．０２５、０．４和０．４ｍｇ／Ｌ。５０、１００、２００ｍｇ／Ｌ氧氟沙星、５０ｍｇ／Ｌ恩诺沙星、５０ｍｇ／Ｌ洛美沙星和１００ｍｇ／Ｌ强力霉素连续５ｄ饮水给药,对人工合并感染败血霉形体和大肠杆菌病鸡的治愈率分别是９３．３％、９６．７％、９６．７％、１００％、９６．７％和８３．３％,感     

Acquired immunity to Eimeria tenella in lasalocid-treated chickens

The effect of restricted medication with lasalocid sodium on the development of acquired immunity against Eimeria tenella was evaluated. The medication was allowed for all or part of 6-day test period (one day before until 4 days after infection). The parameters used for such evaluations were lesion score, caecal, bursal and splenic weights. The optimum treatment time for the drug was clearly indicated by lesion score which was very low when the medication was initiated 1 day before until 1 day after inoculation, but only partly effective if given on Day 2 post-inoculation. The challenge with higher doses on 14th day of immunizing infection revealed a reverse picture where the higher lesions were recorded by the groups where medication was started earlier than the delayed treatment groups. This indicates partial interference with the development of immunity in the earlier treatment groups. Birds treated on Day 4 p.i. were not significantly different (P less than 0.05) from the infected unmedicated control group, suggesting no interference in acquired immunity. A correlation was noticed between day of treatment, the lesion score and weight gain of the caecum as well as the spleen. After both immunizing and challenge infections, the bursa did not show any significant variation in weight, whereas the weight of the spleen did vary. The infected unmedicated group and the delayed-treatment groups had a comparatively higher splenic weight than the uninfected unmedicated group of birds.(ABSTRACT TRUNCATED AT 250 WORDS)     

Prevalence of Mycoplasma gallisepticum and M. synoviae in commercial layers in southern and central California

The prevalence of Mycoplasma gallisepticum (MG) and M. synoviae (MS) in commercial pullet and layer flocks in Southern and Central California was estimated by testing serum and egg-yolk samples from 360 sample flocks in Southern California and 41 sample flocks in Central California. Data relating to potential risk factors associated with MG and MS infections were collected. The estimated true prevalence rate of MG was 73% in Southern California and 3% in Central California. The estimated true prevalence rate of MS was 91% in Southern California and 32% in Central California. Compared with uninfected flocks, MG-infected flocks in Southern California were significantly older and were medicated less (P less than 0.05). More managements were under a multiple-age system, more flocks had molted, more were vaccinated with F-strain, and more had concurrent infection with MS (P less than 0.05). Only one sample flock in Central California was MG-infected; none were vaccinated with F-strain. In Southern California, MS-infected flocks were older than uninfected flocks, more had molted, more were medicated, and more had concurrent infection with MG (P less than 0.05). In Central California, MS-infected flocks did not differ significantly from uninfected flocks in any factor examined; the lack of statistical significance may be due to small sample size.     

Anthelmintic treatment of dairy cows and its effect on milk production.

The results of more than 80 experiments on gastrointestinal parasitism and the impact of anthelmintic treatment on milk production in dairy cattle were reviewed. Abattoir surveys of culled dairy cows, faecal egg counts in milking cows, and serological tests and worm counts in cull cows in milk production studies were collated to assess the level of parasitism in dairy herds. The studies were divided into four general categories: induced infections in previously uninfected cattle; naturally infected cattle treated in mid-lactation; naturally infected cattle treated one to three times during the dry period and/or just before or just after parturition; and naturally infected cattle treated repeatedly from early lactation or given strategic treatments throughout the year. In most studies, the milk production of anthelmintic-treated cattle was compared with that of untreated controls. The anthelmintics investigated included members of the organophosphate, benzimidazole, imidazothiazole and macrocyclic lactone groups. The number of experiments in which the medicated (or uninfected) group had a higher milk yield was compared with the number of experiments in which the control (or infected) group had a higher yield. Overall, the studies demonstrated that grazing dairy cattle are likely to be infected with gastrointestinal nematode parasites, usually Ostertagia ostertagi and Cooperia species. These infections may be present as inhibited larvae, and a periparturient or spring rise is associated with their emergence. There is, at present, no reliable means of determining whether a cow or a herd may be parasitised subclinically at a level sufficient to interfere with milk production. In 70 of 87 experiments (80 per cent) there was an increase in milk production (P < 0.001) after anthelmintic treatment, with a median increase of 0.63 kg/day. In each of the four trial categories, a majority of the studies showed that anthelmintic treatment increased milk production. The yield of milk fat by the medicated cows was greater than by the controls in 26 of the 35 experiments in which that variable was studied (P < 0.01).     

Field trial on the therapeutic efficacy of paromomycin on natural Cryptosporidium parvum infections in lambs

The objective of this study was to evaluate the therapeutic efficacy of paromomycin against cryptosporidiosis in naturally infected lambs under field conditions. The 36 cross-bred neonatal lambs, 3-10 days old, were used. On the first day that lambs showed diarrhea (Day 1) they were randomly divided into three groups. The infected control group (14 lambs) remained unmedicated whereas the two other groups were orally medicated with paromomycin solution (Humatin((R)), Parke Davis, France): 12 lambs (Group A) at 100mg/kg per day for three consecutive days (Days 1-3) and 10 lambs (Group B) at 200mg/kg per day for two days (Days 1 and 2). Drug efficacy was assessed by evaluating the presence of diarrhea, oocyst shedding and weight gains from Days 1 to 23. The results show the efficacy of paromomycin in reducing both cryptosporidial oocyst output and severity of clinical signs. On Day 4, all unmedicated lambs remained infected and excreted large numbers of cryptosporidial oocysts (mean score: 2.5) whereas oocyst output had stopped in most medicated lambs (>60%) and low numbers of oocysts were excreted in the remaining lambs (mean score: 0.45 in Group A and 1 in Group B). Mean oocyst excretion was significantly reduced in medicated lambs from Days 2 to 5 (P<0.05). Treatment also reduced, but not completely prevented, clinical symptoms although diarrhea stopped in most medicated lambs just after drug withdrawal. The mean weight gains of Group A lambs were higher than that of unmedicated lambs throughout the study and statistically significant differences were found from Days 1 to 11 (1.99+/-0.81 versus 1.47+/-0.53) (P<0.05). By contrast, the growth rate of Group B lambs from Days 11 to 23 was impaired when compared with the two other groups (P<0.05) although no significant differences were found at the end of the study (Days 1-23).     

Control of Salmonella enteritidis phage type 4 experimental infection by fosfomycin in newly hatched chicks

One hundred and twenty 1-day-old broiler chickens were divided into four groups: group I unmedicated and orally challenged with 1.5×10⁸ cfu of Salmonella enteritidis phage type 4; group F infected and treated with 300 ppm of fosfomycin in their drinking water; group CF uninfected and treated, and group C maintained as a control group. Their performance, clinical signs, S. enteritidis PT4 reisolation and biochemistry variables were compared. Group F showed fewer symptoms and gross lesions than those from group I. Fosfomycin treatment at 300 ppm improved body weight at 7 days of age by 42.3%. S. enteritidis PT4 reisolation in group I was higher than in the treated group, but total decontamination of challenged birds was not achieved. There was an increase in the levels of total protein and globulins in group I but not in the treated group. Fosfomycin caused no adverse effects on chickens from group CF, assessed by performance and biochemical variables. The results indicate that fosfomycin could be used in the treatment of S. enteritidis PT4 experimental infection.